International Journal of Medical and Pharmaceutical Sciences
Open access peer-reviewed Journal
Volume 2, Issue 4, Page 100-117.
https://doi.org/10.5281/zenodo.19475061

Review Article

Targeted and Immune-Based Therapies in Leukemia: Current Status and Future Prospects

Kartik, Rajinderpal Kaur, Nisha*

School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, India

In recent years, the treatment of leukemia has been changing from non-specific, traditional chemotherapies into selective therapies and immune-based therapies. Advances in molecular medicine have enabled the development of methods in precision oncology that take advantage of the unique genetic and signaling abnormalities that drive leukemogenesis. Tyrosine kinase inhibitors (TKIs), particularly those that target BCR-ABL1 in chronic myeloid leukemia (CML), have completely altered the natural course of CML. Where previously CML was an acute presentation, TKIs converted it into a chronic disorder that is manageable. Other targeted therapies that will be discussed in the following review are FLT3, IDH1/2, and BCL-2 inhibitors. These therapies are generally less toxic and produce longer duration of survival than older therapeutic regimens. Immune-based therapies including monoclonal antibodies, antibody-drug conjugates, bispecific T-cell engagers, as well as CAR-T cells have demonstrated remarkable efficacy for this patient population and again, particularly for patients who have relapsed or are refractory to therapy for acute lymphoblastic leukemia (ALL) or chronic lymphocytic leukemia (CLL). Combination strategies, particularly combining focused and immune-based therapies with chemotherapy, have achieved greater remission depths and broader cure possibilities for patients with historically poor outcomes. Even with this progress, clinical issues such as mechanisms of resistance due to kinase domain mutations and immune evasion remain important challenges in the clinic. In addition to these challenges, considerations of toxicity, access, and cost will also limit widespread use. Clinical studies continue to explore the newest generation of agents, new molecular targets, and cellular therapies that can easily be scaled to address residual gaps in treatment.

Keywords: Leukemia; Targeted therapy; Immune-based therapy; Precision oncology; Tyrosine kinase inhibitors (TKIs); CAR-T cell therapy; Combination therapy; Drug resistance; Personalized medicine; Artificial intelligence (AI).

INTRODUCTION

The purpose and focus of this review is to offer a broad appraisal of the cutting-edge therapies targeting leukemia through targeted and immune-based modalities, especially looking at their implications for clinical practice, advantages over conventional chemotherapy, and current barriers to success.[ ] We will discuss the biological basis for targeted therapies, review important clinical trials and agents that have become approved, and look at ongoing investigational therapies that will shape the future of leukemia care.[ ] Additionally, we will thoughtfully evaluate the current limitations of these new approaches, including resistance, toxicity, accessibility, and cost to provide an objective view on their place in the standard of care.[ ] Overall, by collectively reviewing the observation of translational research and clinical practice, this review would like to emphasize how advances in molecular medicine and immuno-oncology continue to advance the field toward the development of precision oncology.[ ] This includes situating the advances in caring for the patient with leukemia within an umbrella of time when science through biology-based targeting and biological-based immune modulation is rapidly changing.[ ]The rationale for Therapies that are targeted and immune-based in leukemia is due to a greater understanding of its molecular pathogenesis and the role of the immune

system in controlling the disease.[ ] Targeted therapy approaches target specific genetic or signaling abnormalities that drive leukemogenesis. An example of this is the development of tyrosine kinase inhibitors (TKIs), such as imatinib, which changed CML care by targeting the BCR-ABL1 fusion protein and changing CML from an acute malignant disease into a manageable chronic disease. [ ] Similarly, agents targeting FLT3, IDH1/2, and BCL-2 mutations in AML have expanded therapeutic care with improved survival and reduced toxicity compared to traditional care.[ ] On the immunology side, regimens involving monoclonal antibodies, antibody–drug conjugates, bispecific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR) T cells have demonstrated efficacy, primarily in refractory and relapsed ALL and CLL. [ ] Using or stimulating the patient's immune system, these strategies offer a new and effective method of utilizing leukemic cell elimination with potential long-lasting remission due to immune memory. Checkpoint inhibitors and vaccinations integrated with leukemic care further highlight the expanding armamentarium of immune-based strategies. [ ] The purpose and focus of this review are to offer a broad appraisal of the cutting-edge therapies targeting leukemia through targeted and immune-based modalities, especially looking at their implications for clinical practice, advantages over conventional chemotherapy, and current barriers to success.[ ] We will discuss the biological basis for targeted therapies, review important clinical trials and agents that have become approved, and look at ongoing investigational therapies that will shape the future of leukemia care.[ ] Additionally, we will thoughtfully evaluate the current limitations of these new approaches, including resistance, toxicity, accessibility, and cost to provide an objective view on their place in the standard of care.[ ] Overall, by collectively reviewing the observation of translational research and clinical practice, this review would like to emphasize how advances in molecular medicine and immuno-oncology continue to advance the field toward the development of precision oncology.[ ]This includes situating the advances in caring for the patient with leukemia within an umbrella of time when science through biology-based targeting and biological-based immune modulation is rapidly changing.[ ]

2. Molecular Pathogenesis and Therapeutic Targets

Facilitated by a host of genetic, epigenetic, and microenvironmental changes that result in altered normal hematopoiesis and ultimately malignant clonal expansion, the initiation and evolution of leukemia is a multistep process.[ ] Genetic mutations are important drivers of leukemogenesis and often involve recurrent chromosomal translocations, insertions, deletions, or point mutations that result in changes to critical regulators of cell growth and survival.[ ] An illustrative example is the BCR-ABL fusion gene due to the translocation of the Philadelphia chromosome, resulting in a constitutively active tyrosine kinase, and is responsible for virtually [ ] all cases of chronic myeloid leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL). Similarly, activating mutations in FLT3 are among the most common in acute myeloid leukemia (AML) leading to aggressive disease and poor prognosis. [ ] Mutations in the metabolic enzymes IDH1 and IDH2 result in the accumulation of the oncometabolite 2-hydroxyglutarate, leading to epigenetic reprogramming and defective differentiation, and mutations in TP53 are associated with chemotherapy resistance and poor outcomes across leukemia subtypes.[ ]

2.1 Tyrosine Kinase Inhibitors (TKIs)

The most successful case of targeted therapy in leukemia has been the development of tyrosine kinase inhibitors.

BCR-ABL Inhibitors: Chronic myeloid leukemia (CML) is driven by the BCR-ABL fusion gene, which encodes a constitutively active tyrosine kinase. [ ] Imatinib, the first approved TKI, transformed management of CML and resulted in durable remissions while converting the disease from an acute, fatal condition to a manageable chronic disease. [ ] Resistance can arise from kinase domain mutations, including T315I, leading to the development of second-generation TKIs (dasatinib and nilotinib) and third-generation inhibitors (Ponatinib), which effectively target resistant clones. [ ] These agents are additionally used in Philadelphia for chromosome-positive acute lymphoblastic

leukemia (Ph+ ALL), where they have improved survival along with chemotherapy or monoclonal antibodies.[ ]

FLT3 Inhibitors: Mutations in FLT3, especially internal tandem duplications (ITD), occur in approximately 30% of patients with AML and are associated with an overall poor prognosis. [] Midostaurin improved overall survival with chemotherapy in the RATIFY trial and subsequently became the first FDA approved FLT3 inhibitor. For patients with relapsed/refractory AML, gilteritinib has demonstrated superior outcomes compared to salvage chemotherapy, establishing it in standard practice. [ ]

BTK Inhibitors: Bruton's tyrosine kinase (BTK) signaling is a critical component of B-cell receptor signaling and survival in patients with CLL. [ ] As a first-in-class covalent BTK inhibitor, ibrutinib has greatly improved outcomes in CLL, mantle cell lymphoma, and Waldenström macroglobulinemia. Newer BTK inhibitors such as acalabrutinib and Zanubrutinibdemonstrate comparable efficacy but reduced off-target toxicities, ultimately allowing for more therapeutic options for patients who are intolerant to ibrutinib. [ ]

2.2 IDH Inhibitors

Mutations in the genes IDH1 and IDH2 are noted in a subset of AML and lead to the accumulation of the oncometabolite 2-hydroxyglutarate (2HG), which inhibits DNA and histone methylation and blocks differentiation. [ ] Ivosidenib (IDH1 inhibitor) and enasidenib (IDH2 inhibitor) induce leukemic differentiation and show meaningful efficacy for patients with relapsed/refractory AML, with manageable toxicity including differentiation syndrome.[ ]

2.3 BCL-2 Inhibitors

The anti-apoptotic protein BCL-2 is overexpressed in CLL and subsets of AML to help leukemic cells survive. [ ] The selective BCL-2 inhibitor venetoclax has changed how we treat elderly or unfit AML patients when paired with hypomethylating agents (azacitidine or decitabine), resulting in high rates of remission.[ ] Venetoclax induces deep remissions with MRD-negativity in CLL as monotherapy or in combination with anti-CD20 mAbs, at times allowing for time-limited treatment strategies.[ ]

2.4 Epigenetic Modifiers

Abnormal epigenetic mechanisms are prominent in leukemia, and consequently there is interest in therapies that target aberrant epigenetic mechanisms. [ ] Hypomethylating agents, such as azacitidine and decitabine, are well-established referenced drugs for the treatment of AML and myelodysplastic syndromes, where they restore normal gene expression and promote differentiation.[ ] Histone deacetylase (HDAC) inhibitors are less well-established, but they may also form part of combination regimens for AML and ALL, especially since they may enhance differentiation and overcome resistance.[ ]

2.5 Additional Small Molecule Inhibitors

Other pathways believed to contribute to leukemogenesis, such as the PI3K/AKT/mTOR, JAK/STAT, and RAS/MAPK pathways, are being studied further. [ ] While PI3K inhibitors (idelalisib and duvelisib) have demonstrated efficacy in chronic lymphocytic leukemia (CLL), toxicity is an issue.[ ] In leukemias with abnormal cytokine signaling, JAK inhibitors (ruxolitinib) are being studied. In addition, new small molecules targeting Menin–MLL interactions or mutant RAS pathways may be effective for genetically defined subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). [ ]



Fig 1: Leukemia Molecular Pathogenesis And Therapeutic Target

3. Immune-Based Therapies for Leukemia

The emergence of therapies that are immune based has ushered a new era in the management of leukemia through the utilization of the body's own immune system to recognize and kill malignant cells. [ ] These therapies vary greatly, spanning from monoclonal antibodies to engineered cellular therapies, and have shown amazing success in subsets of patients with relapsed disease despite chemotherapy or targeted inhibitors. [ ]

3.1 Monoclonal Antibodies

Monoclonal antibodies (mAbs) are among the earliest immune-based therapies utilized and are widely utilized. [ ] They target specific antigens that reside on the surface of leukemic cells and induce cytotoxicity primarily through either complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, or direct interference with signaling.[ ]

Anti-CD20 Antibodies: By combining with chemotherapy backbones, Rituximab was the first anti-CD20 antibody to significantly alter the treatment of CLL, leading to deeper remissions and better survival than previously seen. [] A next-generation CD20 antibody, obinutuzumab, improved upon this foundational development by demonstrating enhanced antibody-dependent cellular cytotoxicity and superior outcomes in CLL, including treatment in high-risk populations.[ ]

Anti-CD33 Antibodies: Gemtuzumab ozogamicin is an antibody–drug conjugate targeting CD33, an antigen whose expression is significantly higher on AML blasts. [ ] Although approved initially, the drug was withdrawn after approval for toxicity concerns. Revised dosing schedules significantly improved survival upon combination with chemotherapy, and Gemtuzumab ozogamicin was re-approved for use clinically. [ ]

Anti-CD52 Antibodies: Alemtuzumab, an antibody targeting CD52, has a role in treating an older patient population with relapsed CLL; unfortunately, it is restricted due to causing profound immunosuppression and infectious complications—thus limiting its use in select populations. [ ]

3.2 Bispecific T-cell Engagers (BiTEs)

BiTEs are designed proteins that bind to a tumor antigen in concert with CD3 on T-cells, thus

redirecting T-cell mediated cytotoxicity against leukemic cells.[ ] Blinatumomab, the first-in-class CD19/CD3 BiTE, has revolutionized the treatment of relapsed/refractory B-ALL, leading to impressive rates of minimal residual disease (MRD) negativity and durable remissions in both adults and children.[ ] Current clinical trials are assessing new BiTE molecules targeting other antigens, notably CD20, CD22 and CD123 to expand the treatment of leukemias. [ ]

3.3 Antibody–Drug Conjugates (ADCs)

ADCs attach monoclonal antibodies to cytotoxic chemotherapeutic agents and thus selectively deliver chemotherapy to malignant cells while sparing normal tissue. [] In the context of leukemia, gemtuzumab ozogamicin is the first and most notable example with promising clinical results in AML. [ ] Other ADCs targeting CD22 in ALL and CD123 in AML are being explored despite challenges with safety and efficacy.[ ]

Table-1: Antibody-Based Immunotherapeutic Approaches in Leukemia: Targets, Mechanisms, and Clinical Impact

Therapy Type	Example(s)	Target Antigen	Mechanism of Action	Clinical Significance	Ref no.
Monoclonal Antibodies (mAbs)	Rituximab	CD20	Induces complement-dependent and antibody-dependent cellular cytotoxicity; interferes with cell signaling	Combined with chemotherapy; improved remission and survival in CLL	
	Obinutuzumab	CD20	Enhanced antibody-dependent cellular cytotoxicity (ADCC) compared to Rituximab	Superior outcomes in high-risk CLL patients	
	Gemtuzumab ozogamicin	CD33	Antibody–drug conjugate delivering cytotoxic agent to AML cells	Initially withdrawn for toxicity; re-approved after revised dosing showed improved survival in AML	
	Alemtuzumab	CD52	Causes profound lymphocyte depletion	Effective in relapsed CLL (elderly), but limited by severe immunosuppression and infection risk	
Bispecific T-cell Engagers (BiTEs)	Blinatumomab	CD19 (tumor) and CD3 (T-cell)	Redirects T-cell mediated cytotoxicity to leukemic cells	Achieved high MRD-negativity and durable remissions in relapsed/refractory B-ALL (adults & children)	
	(Under clinical trials)	CD20, CD22, CD123	Similar BiTE approach targeting different antigens	Expanding therapeutic scope to other leukemias	
Antibody–Drug Conjugates (ADCs)	Gemtuzumab ozogamicin	CD33	Monoclonal antibody linked to cytotoxic drug for targeted delivery	Proven efficacy in AML; major milestone ADC	
	(Under exploration)	CD22 (ALL), CD123 (AML)	Selective delivery of cytotoxic agents to malignant cells	Promising, but still facing safety and efficacy challenges	

4.4 Immune Checkpoint Inhibitors

Immune checkpoint pathways such as PD-1/PD-L1 and CTLA-4 physiologically down-regulate T-cell function to limit autoimmunity, but many leukemic cells can also hijack these pathways to evade immune surveillance. [ ] Checkpoint inhibitors have demonstrated notable efficacy in solid tumors and

Hodgkin lymphoma, but experience with their use for leukemias is more limited.[ ] Initial studies of PD-1 inhibitors (nivolumab, pembrolizumab) in AML and CLL reported modest activity as monotherapy. However, PD-1 inhibitors in combination with hypomethylating agents or vaccines may provide more encouraging results. [ ] Such studies face challenges related to variable expression of the immune checkpoint ligands in leukemia and exposure to immune-mediated adverse events in heavily immunosuppressed patients.[ ]

4.5 CAR-T Cell Therapy

Chimeric antigen receptor (CAR)-T cell therapy is an innovative approach to adoptive immunotherapy. [ ] CAR-T cell therapy involves genetically modifying T-cells obtained from the patient's own blood to express synthetic receptors to engage in specific, leukemia-associated antigens. CAR-T cell treatment can result in sustained and profound remissions. [ ]

CD19-Directed CAR-T Cells: The first CAR-T therapy, tisagenlecleucel, was FDA-approved in 2017 for use in pediatric and young adult patients with relapsed/refractory B-ALL, which is the cause of 80% of ALL cases and, as such, extremely common in this population. [] Tisagenlecleucel, or Kymriah, has demonstrated remarkable response rates, with confirmed remission rates greater than 80%. [ ] Other similar therapies have also shown efficacy in relapsed/refractory CLL, but the responses are more limited than what we have seen in B-ALL.[ ]

CAR-T in AML: CAR-T design and development, on the other hand, has been more difficult and prolonged compared to other malignancies, due to the absence of AML-specific antigens and due to the potential consequence of targeting normal hematopoietic progenitors which can lead to life threatening cytopenias. Trials targeting other antigens like CD33 and CD123, and other candidate markers are ongoing. [ ]

Toxicities and Management: The most substantial toxicities seen with CAR-T therapies are cytokine release syndrome (CRS) and neurotoxicity this is consistent across patient populations. [ ] The first, CRS, is a result of rapid-release of pro-inflammatory cytokines when CAR-T cells are activated. Fever, hypotension, and organ dysfunction are some of the initial clinical symptoms to develop. [ ] Neurotoxicity can be seen as confusion, hallucinations, seizures, and cerebral edema. The management strategies involving the early use of tocilizumab, a humanized IgG1 monoclonal antibody targeting the IL-6 receptor for autoimmune diseases, alongside corticosteroids and supportive care, were established at this time.[ ] There are ongoing developments for CAR-T design, such as the incorporation of safety switches in addition to next-generation CAR-T constructs, that may enhance efficacy but may also reduce potential toxicities as well.[ ]

4. Combination Strategies

The combination of targeted and immune-based therapies with standard treatment represents a new paradigm in management of leukemia.[ ] Although single agent targeted therapies have shown compelling efficacy in certain populations, there is still a majority of patients who relapse, showing that combination strategies are a rational clinical approach.[ ] Combination strategies can leverage synergistic mechanisms of action to provide deeper, more durable remissions, and improved survival, while reducing the risk of subsequent relapse in different populations.[ ]



Fig 2: Combination Leukemia Therapy

4.1 Combining Targeted Therapy and Chemotherapy

One progression in treatment is combining a tyrosine kinase inhibitor (TKI) with the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).[ ] Historically, this subtype had poor outcomes with chemotherapy treatment alone, but the addition of imatinib or dasatinib to induction treatment regimens has improved remission and survival, and, in some cases, the need for allogeneic stem cell transplant.[ ] Similarly, midostaurin with standard "7+3" chemotherapy significantly improved survival in FLT3-mutated AML in the RATIFY trial, establishing midostaurin as the standard of care.[ ] These examples illustrate how chemotherapy can debulk disease and reduce clonal heterogeneity, while targeted therapy can eliminate genetically defined driver clones.[ ]

4.2 Targeted + Immune-Based Treatments

The use of targeted inhibitors in combination with immune-based treatments has been particularly exciting.[ ] In CLL, ibrutinib (a BTK inhibitor) decreases the leukemic burden and enhances T-cell function, thus creating a synergistic effect when combined with anti-CD20 antibodies, such as rituximab or obinutuzumab.[ ] In the MURANO study, the combination of venetoclax with rituximab demonstrated unprecedented MRD-negative remissions in relapsed/refractory CLL, providing additional support for a time-limited combined strategy in lieu of indefinite therapy. [ ]

4.3 Venetoclax + Hypomethylating Agents in AML

The perhaps most paradigm shifting example in elderly AML has been the use of venetoclax with azacitidine or decitabine, inducing 60-70% [ ] complete remission rates in a population historically considered unfit for intensive chemotherapy, and leading to regulatory approval. Mechanistically, hypomethylating agents sensitize leukemic cells to venetoclax by prime leukemic cells for apoptosis via altered modulation of BCL-2 family proteins.[ ] One clinical barrier is the development of resistance via upregulation of alternatives to apoptosis (MCL-1, BCL-XL) that warrants investigation for triple-agent regimens.[ ]

4.4 Justification for Synergy and Current Studies

The logic behind combination therapy is to target multiple traits of leukemogenesis at once: chemotherapy reduces the tumor burden, targeted inhibitors shut down the oncogenic activity, and immunotherapies recruit and engage the host response to assist with the fight against the cancer.[ ] Ongoing clinical trials involve novel combinations such as using FLT3 inhibitors and checkpoint blockade in the setting of AML, PI3K inhibitors with CAR-T therapy

in CLL, or incorporating venetoclax-based triplets with innovative agents.[ ] These trials are part of an overall movement for personalized, mechanism-based regimens designed to optimize efficacy and limit toxicity.[ ] The bottom line is that combination strategies have changed therapeutic paradigms in leukemia through improved depth of responses, reduced relapse, and clinically curative strategies for populations of patients with largely limited therapeutic options.[ ] The future will involve refinement of regimens, including biomarker-driven patient selection and real-time resistance mechanisms for monitoring.[ ]

5. Resistance Mechanisms and Challenges

Despite significant progress with targeted and immune therapies, resistance remains a significant challenge for durable disease control in leukemia. [ ] Resistance can be primary (i.e., no response at onset) or acquired (i.e., an initial response followed by relapse).[ ] Understanding mechanisms of resistance is paramount to addressing therapy selection and developing next generation agents. [ ]

5.1 Resistance to Targeted Therapies

TKIs represent both the success and limitations of therapeutic targeting. In CML, resistance to first-generation imatinib is usually a consequence of mutations in the BCR-ABL kinase domain, [] including the highly discussed T315I mutation, which prevents binding to imatinib, for example. In AML, the same is true for FLT3, where secondary kinase mutations are the basis for resistance, or activation of parallel signaling pathways (i.e., RAS/MAPK or PI3K/AKT) restore leukemic cell survival. [ ] In CLL, the main mechanism of resistance to ibrutinib typically resides from mutations in BTK (C481S) but can also include downstream molecules (PLCG2). Venetoclax resistance often is due to the upregulation of alternative anti-apoptotic proteins, such as MCL-1 or BCL-XL, to reduce dependency on BCL-2. [ ]

5.2 Immune Evasion and Tumoral Heterogeneity

Immune-based therapies are confronted by distinct resistance mechanisms.[ ] In CAR-T therapy, the loss of antigen or downregulation of CD19 is a well-reported cause of relapse in B-ALL.[ ] Concern also arises as leukemic cells may upregulate checkpoint molecules (for example, PD-L1) or recruit other immune cells (i.e., regulatory T cells and myeloid-derived suppressor cells) to create a microenvironment that inhibits immune activation.[ ] Tumor heterogeneity further complicates therapy: selective pressure can lead to disease relapse through the emergence of sub clonal populations with different mutations or antigen profiles.[ ]

5.3 Toxicities and Management Consideration

Toxicity is another important consideration. TKIs can lead to vascular events or bleeding or cytopenias which may limit their long-term utilization.[ ] Furthermore, venetoclax has been linked to a risk of tumor lysis syndrome in CLL with high tumor burden necessitating a drug ramp-up and monitoring period.[ ] Finally, immune-based therapies can lead to engraftment cytokine release syndrome (CRS) or neurotoxicity requiring protocols and special management with agents such as tocilizumab or corticosteroids.[ ] As such, managing efficacy and safety will be central to the overall decision-making process regarding therapy.[ ]

6. Ongoing Clinical Trials and Newly Developed Treatments

The rapid translation of research into clinical practice in leukemia has resulted in the highest number of clinical trials studying novel therapies. [ ] These trials seek to improve current standard strategies, provide alternatives to resistance, and evaluate next-generation methods of treatment.[ ]

6.1 Ongoing Clinical Trials of Importance

FLT3 inhibitors in AML: The QuANTUM-First trial (NCT02668653) is currently investigating quizartinib in combination with standard chemotherapy in newly diagnosed FLT3-ITD–positive AML and has previously reported promising preliminary data. [ ]

Venetoclax-based Regimens: Multiple trials (e.g., NCT02993523) are currently investigating venetoclax - in combination with hypomethylating agents, FLT3 inhibitors, or IDH inhibitors in patients with AML - and are designed to overcome resistance and extend the drug's benefit. [ ]

BTK Inhibitors in CLL: Next-generation BTK inhibitors such as zanubrutinib and pirtobrutinib in patients in randomized studies (NCT03740529) assessing their efficacy and safety in relapsed/refractory CLL versus ibrutinib. [ ]

BiTEs and ADCs: New bispecific antibodies targeting CD20, CD22, and CD123 are in commercial study (e.g., NCT04104682) with the goal of replicating the success of blinatumomab for acute leukemias. [ ]

6.2 Next-Generation CAR-T and Cellular Therapies

Research has transitioned beyond the first-generation CAR-T cells. Dual-target CAR-Ts (e.g., targeting CD19/CD22) are in clinical trials to mitigate antigen-loss relapse, and "armored" CAR-T are developed to provide a cytokine signaling module to augment persistence. [] Allogeneic CAR-T cells ("off-the-shelf" approaches) are also being developed and will deliver scalable strategies to address the challenges associated with autologous manufacturing. [ ]

6.3 Novel Targets in Development

Novel targets in development include inhibition of Menin–MLL interactions in KMT2A-rearranged leukemias, RAS/MAPK pathway inhibitors in RAS-mutated acute myeloid leukemia (AML), and CD47 blockade ("don't eat me" signal) with magrolimab for AML and myelodysplastic syndromes (MDS). [ ] These agents reflect a movement towards precision oncology in which the treatment is individualized based on the molecular and/or immunological profile of the patient.[ ]

Table 2: Emerging and Investigational Therapeutic Strategies in Leukemia: Ongoing Clinical Trials, Advanced Cellular Therapies, and Novel Molecular Targets

Category	Example(s)/ Trial Name	Target/Focus	Mechanism/Strategy	Clinical Significance/Purpose	Ref no.
Ongoing Clinical Trials of Importance	FLT3 Inhibitors (QuANTUM-First; NCT02668653)	FLT3-ITD in AML	Quizartinib + standard chemotherapy	Promising data; aims to improve survival in newly diagnosed FLT3-ITD–positive AML	[i]
	Venetoclax-based Regimens (e.g., NCT02993523)	BCL-2 inhibition	Venetoclax combined with hypomethylating agents, FLT3 or IDH inhibitors	Designed to overcome resistance and extend therapeutic benefit in AML	[ii]
	BTK Inhibitors (NCT03740529)	BTK in CLL	Zanubrutinib and PirtobrutinibvsIbrutinib	Evaluates next-generation BTK inhibitors for improved efficacy and safety in relapsed/refractory CLL	[iii]
	BiTEs and ADCs (e.g., NCT04104682)	CD20, CD22, CD123	Bispecific T-cell engagers and antibody-drug conjugates	Aims to replicate the success of Blinatumomab in acute leukemias	[iv]
Next Generation CAR-T and Cellular Therapies	Dual-target CAR-T (CD19/CD22)	CD19 and CD22	Dual antigen targeting to prevent antigen-loss relapse	Enhances response durability and reduces relapse risk	[v]
	Armored CAR-T Cells	Cytokine signaling enhancement	Engineered with additional cytokine modules	Increases CAR-T persistence and anti-tumor activity	[vi]
	Allogeneic (“Off-the-shelf”) CAR-T Cells	Donor-derived universal CAR-T	Ready-made cell therapy platform	Provides scalable and rapid treatment compared to autologous CAR-T manufacturing	[vii]

Novel Targets in Development	Menin–MLL Inhibitors	KMT2A (MLL)-rearranged leukemias	Blocks Menin–MLL interaction	Targets genetic subtype of leukemia for precision therapy	[viii]
	RAS/MAPK Pathway Inhibitors	RAS-mutated AML	Inhibits RAS/MAPK signaling	Counteracts oncogenic RAS-driven leukemogenesis	[ix]
	CD47 Blockade (Magrolimab)	CD47 ("don't eat me" signal)	Promotes macrophage-mediated phagocytosis	Active in AML and MDS; enhances immune clearance of cancer cells	

7. Future Plans and Outlook

Leukemia therapy is being transformed by precision medicine, technology innovation, and progress in understanding resistance and immune regulation.

7.1 Precision Medicine and Biomarker-Guided Therapy

More comprehensive genomic and epigenomic profiling is informing more therapeutic decision making. The ability to detect driver mutations and resistance mechanisms in real time with next-generation sequencing is facilitating adaptive treatment selection. Biomarkers, such as minimal residual disease (MRD) status, are entering clinical trials as a primary endpoint, and may soon replace overall survival as the "gold standard".

7.2 Artificial Intelligence and Genomics

We are using artificial intelligence (AI) and machine learning tools to analyze large genomic datasets, predict drug sensitivity, and to personalize therapy. AI-derived algorithms can also reveal patterns of resistance and optimize combinations, adding a new component of clinical decision making.

7.3 Off-The-Shelf Cellular Therapies

Autologous CAR-T cell therapy is limited by time delaysin manufacturing, cost, and patient fitness. The development of allogeneic "off-the-shelf" CAR-T and CAR-NK cells is paving the way for scalable, rapid, and accessible cellular therapy. Early clinical data show comparable efficacy with lower toxicity, though issues such as graft-versus-host-disease remain.

7.4 Resisting Resistance and Promoting Durability

Forward-looking strategies will leverage rational combinations of selective agents, immune therapies, and epigenetic modulators to prevent and/or overcome resistance. There are also new checkpoint inhibitors, dual-target CAR-T constructs, and small molecules targeting resistance pathways (e.g., MCL-1 inhibitors) in development. Maximizing the durability of these therapies will also focus on enhancing immune memory and persistence of cellular therapies.

CONCLUSION

Modern therapeutic paradigms of leukemia have moved into an era of paradigm shift, as they have decisively abandoned conventional and non-specific cytotoxic regimens in favor of precision-targeted and immunologically driven modalities, which play upon the molecular and immune-pathophysiology weaknesses of the disease. The use of technological advances including tyrosine kinase inhibitors, FLT3-specific agents, IDH inhibitors, and BCL-2 antagonists have significantly increased overall survival and quality of life and the use of immunotherapeutic agents including monoclonal antibodies, antibody-drug conjugates, bispecific T-cell engagements, and chimeric antigen receptor T-cell therapies has redefined the potential of remission, even in the relapsed or refractory setting. Although these improvements have been made, certain issues still persist, and they include challenges like resistance -conferring mutations, immune resistance mechanisms, and drug related toxicity in the therapy. Current clinical research, treatment approaches using biomarkers, and AIs-empowered genomic analytics have enhanced the practice of personalized treatments and prediction of resistance. Finally, emerging technologies, molecular medicine, and immuno-

oncology are converting the management of leukemia to more effective, long-term and tailored treatment responses and therapeutic outcomes, which represents a new dawn of possibly curative therapies.

REFERENCES

1. Caracciolo, D., Mancuso, A., Polerà, N. et al. The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives. Exp Hematol Oncol 12, 5 (2023). https://doi.org/10.1186/s40164-022-00368-w
2. Lachowiez, C. A., DiNardo, C. D., & Loghavi, S. (2023). Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance. Cancers, 15(5), 1617. https://doi.org/10.3390/cancers15051617
3. Dalgetty, M., Leurinda, C., & Cortes, J. (2023). A comparative safety review of targeted therapies for acute myeloid leukemia. Expert opinion on drug safety, 22(12), 1225–1236. https://doi.org/10.1080/14740338.2023.2289176
4. AlDoughaim, M., AlSuhebany, N., AlZahrani, M., AlQahtani, T., AlGhamdi, S., Badreldin, H., & Al Alshaykh, H. (2024). Cancer biomarkers and precision oncology: A review of recent trends and innovations. Clinical Medicine Insights: Oncology, 18, 11795549241298541.
5. Soleimani Samarkhazan, H., Noormohamadi, H., Shafiei, F. S., Taghinejad, Z., Maleknia, M., Raoufi, A., Nouri, S., & Mohammadi, M. H. (2025). Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens. Clinical and experimental medicine, 25(1), 215. https://doi.org/10.1007/s10238-025-01764-2
6. Restelli, C., Ruella, M., Paruzzo, L., Tarella, C., Pelicci, P. G., & Colombo, E. (2024). Recent advances in immune-based therapies for acute myeloid leukemia. Blood Cancer Discovery, 5(4), 234-248.
7. Ciaffaglione V, Consoli V, Intagliata S, Marrazzo A, Romeo G, Pittalà V, Greish K, Vanella L, Floresta G, Rescifina A, et al. Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia. Molecules. 2022; 27(10):3220. https://doi.org/10.3390/molecules27103220
8. Forsberg, M., & Konopleva, M. (2024). AML treatment: conventional chemotherapy and emerging novel agents. Trends in Pharmacological Sciences, 45(5), 430-448.
9. Cech, P., Skórka, K., Dziki, L., & Giannopoulos, K. (2024). T-Cell Engagers—The Structure and Functional Principle and Application in Hematological Malignancies. Cancers, 16(8), 1580. https://doi.org/10.3390/cancers16081580
10. Restelli C, Ruella M, et al. Recent Advances in Immune-Based.Blood Cancer Discov. 2024;5(4):234-746106. "This review ... covers ... immune checkpoint inhibitors ... therapeutic vaccines ...
11. Bogdanovic, B., Hugonnet, F., & Montemagno, C. (2025). Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy. Cancers, 17(7), 1247. https://doi.org/10.3390/cancers17071247
12. Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., ... & Yang, S. (2021). Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal transduction and targeted therapy, 6(1), 201.
13. Bhansali, R. S., Pratz, K. W., & Lai, C. (2023). Recent advances in targeted therapies in acute myeloid leukemia. Journal of hematology & oncology, 16(1), 29.
14. Alaoui Mdarhri, H., Benmessaoud, R., Yacoubi, H., Seffar, L., Guennouni Assimi, H., Hamam, M., ... & Kettani-Halabi, M. (2022). Alternatives therapeutic approaches to conventional antibiotics: advantages, limitations and potential application in medicine. Antibiotics, 11(12), 1826.
15. Edsjö, A., Holmquist, L., Geoerger, B., Nowak, F., Gomon, G., Alix-Panabières, C., ... & Stenzinger, A. (2023). Precision cancer medicine: Concepts, current practice, and future developments. Journal of internal medicine, 294(4), 455-481.
16. Kerr, A., Key Chekar, C., Ross, E., Swallow, J., & Cunningham-Burley, S. (2021). Personalised

cancer medicine: Future crafting in the genomic era (p. 288). Manchester University Press.
17. Chen, Y., Li, J., Xu, L., Găman, M. A., & Zou, Z. (2022). The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting. Cell Death Discovery, 8(1), 397.
18. Roy, U., & Raghavan, S. C. (2021). Deleterious point mutations in T-cell acute lymphoblastic leukemia: Mechanistic insights into leukemogenesis. International Journal of Cancer, 149(6), 1210-1220.
19. Lima, M. C. P., Hornsby, M. B. D., Lim, C. S., & Cheatham III, T. E. (2023). Computational modeling of stapled coiled-coil inhibitors against Bcr-Abl: toward a treatment strategy for CML. bioRxiv.
20. Lanzetti, L. (2024). Oncometabolites at the crossroads of genetic, epigenetic and ecological alterations in cancer. Cell Death & Differentiation, 31(12), 1582-1594.
21. Jayavel, S., Subramanian, M., Kesavan, P. K., & Jayavel, S. (2025). Current and future of targeted therapies against BCR:: ABL kinases. Journal of the Egyptian National Cancer Institute, 37(1), 12.
22. Tolland, M., Ross, D. M., White, D., Hughes, T. P., & Pagani, I. S. (2025). Lipid Storage and Therapy Resistance in Chronic Myeloid Leukaemia: A Novel Perspective on Targeting Metabolic Vulnerabilities. Cancers, 17(18), 3033.
23. George, B., Chan, K. H., & Rios, A. (2024). Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy. Frontiers in Oncology, 14, 1446517.
24. Xiong, Z. Y., Shen, Y. J., Zhang, S. Z., & Zhu, H. H. (2024). A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens. Hematology, 29(1), 2335856.
25. Macečková, D., Vaňková, L., Holubová, M., Jindra, P., Klieber, R., Jandová, E., & Pitule, P. (2024). Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML. Molecular Biology Reports, 51(1), 521.
26. Kantarjian, H. M., DiNardo, C. D., Kadia, T. M., Daver, N. G., Altman, J. K., Stein, E. M., ... & Ravandi, F. (2025). Acute myeloid leukemia management and research in 2025. CA: a cancer journal for clinicians, 75(1), 46-67.
27. Schmid, V. K., & Hobeika, E. (2024). B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia. Frontiers in Oncology, 14, 1339620.
28. Nayyar, M., Menezes, R. C. B. d., Ailawadhi, S., & Parrondo, R. D. (2025). Chronic Lymphocytic Leukemia: Novel Therapeutic Targets Under Investigation. Cancers, 17(14), 2298.
29. Testa, U., Castelli, G., & Pelosi, E. (2025). Recent Developments in Differentiation Therapy of Acute Myeloid Leukemia. Cancers, 17(7), 1141.
30. Kantarjian, H. M., DiNardo, C. D., Kadia, T. M., Daver, N. G., Altman, J. K., Stein, E. M., ... & Ravandi, F. (2025). Acute myeloid leukemia management and research in 2025. CA: a cancer journal for clinicians, 75(1), 46-67.
31. Kegyes, D., Tat, A., Vizitiu, A. S., Vazar-Tripon, D., Ilie, R., Tigu, A. B., ... & Tomuleasa, C. (2025). Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and/or immune therapies. Cell Death Discovery, 11(1), 379.
32. Cheng, J., Fu, H., Jiang, L., Huang, Y., Zhang, Y., Long, Z., & Jiang, X. (2025). Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation. Frontiers in Medicine, 12, 1638176.
33. Hus, I., Giannopoulos, K., Jamroziak, K., Wolowiec, D., Roliński, J., & Robak, T. (2025). Diagnostic and therapeutic recommendations of the Polish Society of Haematologists and Transfusiologists and Polish Adult Leukemia Group-CLL for chronic lymphocytic leukemia in 2025. Acta Haematologica Polonica, 56(3), 143-172.
34. Shokoohi, M., Ghaderi, M., Mokarami, M., Arian, H., Mohammadnabi, S., & Farokhi, A. (2025). Targeted and epigenetic therapies for

acute myeloid leukemia treatment. Discover Oncology, 16(1), 1711.
35. Li, Q. (2025). Methylation landscape in acute myeloid leukemia upon 5-Azacytidine treatment (Doctoral dissertation).
36. Kunachowicz, D., Tomecka, P., Sędzik, M., Kalinin, J., Kuźnicki, J., & Rembiałkowska, N. (2025). Influence of hypoxia on tumor heterogeneity, DNA repair, and cancer therapy: from molecular insights to therapeutic strategies. Cells, 14(14), 1057.
37. Ehm, P. A., & Rehbach, C. (2025). Relevance of AKT and RAS Signaling Pathways for Antibody–Drug Conjugate Immunotherapies in Acute Lymphoblastic Leukemia. Lymphatics, 3(4), 33.
38. Lin, X., Zhang, Y., Huang, H., Zhuang, W., & Wu, L. (2025). Post-marketing safety concern of PI3K inhibitors in the cancer therapies: an 8-year disproportionality analysis from the FDA Adverse Event Reporting System. Expert opinion on drug safety, 24(8), 925-936.
39. Niscola, P., Gianfelici, V., Giovannini, M., Piccioni, D., Mazzone, C., & Fabritiis, P. D. (2025). Menin inhibitors: new targeted therapies for specific genetic subtypes of Difficult-to-Treat acute leukemias. Cancers, 17(1), 142.
40. Restelli, C., Ruella, M., Paruzzo, L., Tarella, C., Pelicci, P. G., & Colombo, E. (2024). Recent advances in immune-based therapies for acute myeloid leukemia. Blood Cancer Discovery, 5(4), 234-248.
41. Papież, M. A., & Krzyściak, W. (2021). Biological therapies in the treatment of cancer—update and new directions. International journal of molecular sciences, 22(21), 11694.
42. Lu, T., Zhang, J., Xu-Monette, Z. Y., & Young, K. H. (2023). The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma. Experimental Hematology & Oncology, 12(1), 72.
43. Saad, A. A. (2022). Targeting cancer-associated glycans as a therapeutic strategy in leukemia. All Life, 15(1), 378-433.
44. Boccellato, E., Comba, L., Tavarozzi, R., Castellino, C., Foglietta, M., Mattei, D., ... & Castellino, A. (2025). Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells. Cancers, 17(13), 2239.
45. Hallek, M. (2025). Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy. American Journal of Hematology, 100(3), 450-480.
46. Collados-Ros, A., Muro, M., & Legaz, I. (2024). Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms—A Systematic Review. Biomedicines, 12(1), 208.
47. Swaminathan, M., & Cortes, J. E. (2023). Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia. Therapeutic Advances in Hematology, 14, 20406207231154708.
48. Mikulska, M., & Averbuch, D. (2022). CD19, CD20 and CD52. In Infectious Complications in Biologic and Targeted Therapies (pp. 113-151). Cham: Springer International Publishing.
49. Zarezadeh Mehrabadi, A., Tat, M., Ghorbani Alvanegh, A., Roozbahani, F., & Esmaeili Gouvarchin Ghaleh, H. (2024). Revolutionizing cancer treatment: the power of bi-and tri-specific T-cell engagers in oncolytic virotherapy. Frontiers in Immunology, 15, 1343378.
50. Salvaris, R., & Fedele, P. L. (2021). Targeted therapy in acute lymphoblastic leukaemia. Journal of personalized medicine, 11(8), 715.
51. Dykes, K. C., & Ball, E. D. (2025). A review of antibody-based immunotherapy clinical trials for adult acute myeloid leukemia (AML): monoclonal antibodies (mAbs) and beyond. Expert Opinion on Biological Therapy, 25(4), 345-362.
52. Izzo, D., Ascione, L., Guidi, L., Marsicano, R. M., Koukoutzeli, C., Trapani, D., & Curigliano, G. (2025). Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy. Therapeutic Advances in Medical Oncology, 17, 17588359241309461.
53. Collados-Ros, A., Muro, M., & Legaz, I. (2024). Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and

Resistance Mechanisms—A Systematic Review. Biomedicines, 12(1), 208.
54. Dykes, K. C., & Ball, E. D. (2025). A review of antibody-based immunotherapy clinical trials for adult acute myeloid leukemia (AML): monoclonal antibodies (mAbs) and beyond. Expert Opinion on Biological Therapy, 25(4), 345-362.
55. Weide, R., Feiten, S., Chakupurakal, G., Friesenhahn, V., Kleboth, K., Köppler, H., … Heymanns, J. (2019). Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017. Leukemia & Lymphoma, 61(3), 557–566. https://doi.org/10.1080/10428194.2019.1680840
56. Yen-Chou Chen,Paulo Miranda,Yazan K. Barqawi,,Grace E. Fox, Chinenye Chukwu,, Javid Moslehi, Rupal P. O'Quinn, Cardiovascular safety outcomes of chronic lymphocytic leukemia treatments: A systematic and targeted literature review, Critical Reviews in Oncology/Hematology , 215 ,(104877) , (2025).
57. Li, X., Xu, S. N., Qin, D. B., Tan, Y., Gong, Q., & Chen, J. P. (2014). Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials. Annals of oncology: official journal of the European Society for Medical Oncology, 25(2), 455–461. https://doi.org/10.1093/annonc/mdt566
58. Hallek, M. (2025). Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy. American Journal of Hematology, 100(3), 450-480.
59. Gökbuget, N., Dombret, H., Bonifacio, M., Reichle, A., Graux, C., Faul, C., Diedrich, H., Topp, M. S., Brüggemann, M., Horst, H. A., Havelange, V., Stieglmaier, J., Wessels, H., Haddad, V., Benjamin, J. E., Zugmaier, G., Nagorsen, D., & Bargou, R. C. (2018). Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood, 131(14), 1522–1531. https://doi.org/10.1182/blood-2017-08-798322
60. He, J., Zeng, X., Wang, C., Wang, E., & Li, Y. (2024). Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies. MedComm, 5(8), e671.
61. Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., ... & Yu, L. (2025). Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals. Journal of Hematology & Oncology, 18(1), 51.
62. Yu, B., Liu, D. Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia. Biomark Res 7, 24 (2019). https://doi.org/10.1186/s40364-019-0175-x
63. Matson, A. W. (2024). Enhancing IL-15-driven natural killer cell proliferation by targeting the regulatory checkpoint ADAM17 to improve tumor cell killing (Doctoral dissertation, University of Minnesota).
64. Sakowska, J., Arcimowicz, Ł., Jankowiak, M., Papak, I., Markiewicz, A., Dziubek, K., ... & Trzonkowski, P. (2022). Autoimmunity and cancer—Two sides of the same coin. Frontiers in Immunology, 13, 793234.
65. Mamun, M. A. A., Zhang, Y., Zhao, J. Y., Shen, D. D., Guo, T., Zheng, Y. C., ... & Liu, H. M. (2023). LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy. Journal of Biomedical Science, 30(1), 60.
66. Sendker, S., Reinhardt, D., & Niktoreh, N. (2021). Redirecting the immune microenvironment in acute myeloid leukemia. Cancers, 13(6), 1423.
67. Titov, A., Zmievskaya, E., Ganeeva, I., Valiullina, A., Petukhov, A., Rakhmatullina, A., ... & Bulatov, E. (2021). Adoptive immunotherapy beyond CAR T-cells. Cancers, 13(4), 743.
68. Benmebarek, M. R., Cadilha, B. L., Herrmann, M., Lesch, S., Schmitt, S., Stoiber, S., ... & Kobold, S. (2021). A modular and controllable T cell therapy platform for acute myeloid leukemia. Leukemia, 35(8), 2243-2257.
69. Si Lim, S. J., Grupp, S. A., & DiNofia, A. M. (2021). Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic

leukemia. Pediatric blood & cancer, 68(9), e29123.
70. Schultz, L. M., Baggott, C., Prabhu, S., Pacenta, H. L., Phillips, C. L., Rossoff, J., ... & Laetsch, T. W. (2022). Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. Journal of Clinical Oncology, 40(9), 945-955.
71. Sidhu, J., Gogoi, M. P., Krishnan, S., & Saha, V. (2024). Relapsed acute lymphoblastic leukemia. Indian Journal of Pediatrics, 91(2), 158-167.
72. Almotiri A. (2024). CAR T-cell therapy in acute myeloid leukemia. Saudi medical journal, 45(10), 1007–1019. https://doi.org/10.15537/smj.2024.45.10.20240330
73. Morris, E. C., Neelapu, S. S., Giavridis, T., & Sadelain, M. (2022). Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Reviews Immunology, 22(2), 85-96.
74. Shah, D., Soper, B., & Shopland, L. (2023). Cytokine release syndrome and cancer immunotherapies–historical challenges and promising futures. Frontiers in immunology, 14, 1190379.
75. Asghar, M. S., Ismail Shah, S. M., Rani, A., Kazmi, S., Savul, I. S., Ukrani, J., Khan, F., Hasan, C. A., Rathore, N., Syed, M., Keswani, S., Surkasha, F., Mal, D., & Kumar, D. (2023). Toxicities of CAR T-cell therapy: a review of current literature. Annals of medicine and surgery (2012), 85(12), 6013–6020. https://doi.org/10.1097/MS9.0000000000001375
76. Alsaieedi, A. A., & Zaher, K. A. (2025). Tracing the development of CAR-T cell design: from concept to next-generation platforms. Frontiers in Immunology, 16, 1615212.
77. Restelli, C., Ruella, M., Paruzzo, L., Tarella, C., Pelicci, P. G., & Colombo, E. (2024). Recent advances in immune-based therapies for acute myeloid leukemia. Blood Cancer Discovery, 5(4), 234-248.
78. Jin, H., Wang, L., & Bernards, R. (2023). Rational combinations of targeted cancer therapies: background, advances and challenges. Nature Reviews Drug Discovery, 22(3), 213-234.
79. Plana, D., Palmer, A. C., & Sorger, P. K. (2022). Independent drug action in combination therapy: implications for precision oncology. Cancer discovery, 12(3), 606-624.
80. Badar, T., Alkhateeb, H., Aljurf, M., & Kharfan-Dabaja, M. A. (2023). Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era. Current Research in Translational Medicine, 71(2), 103392.
81. Guan, F., Yang, L., Chen, Y., Shi, J., Song, X., Lai, X., ... & Luo, Y. (2024). Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study. Cancer, 130(12), 2139-2149.
82. Tedjaseputra, A., Roy, S., Htun, K., Oh, D., McQuilten, Z., Yeh, P., ... & Shortt, J. (2024). Day-21 bone marrow findings incorrectly designate residual leukaemia in FLT3-mutated acute myeloid leukaemia treated with intensive induction plus midostaurin: a morphology-focused study. Pathology, 56(4), 548-555.
83. Soragni, A., Knudsen, E. S., O'Connor, T. N., Tognon, C. E., Tyner, J. W., Gini, B., ... & National Cancer Institute (NCI) Acquired Resistance to Therapy Network (ARTNet). (2025). Acquired resistance in cancer: towards targeted therapeutic strategies. Nature Reviews Cancer, 1-21.
84. Guo, C. X., Huang, X., Xu, J., Zhang, X. Z., Shen, Y. N., Liang, T. B., & Bai, X. L. (2021). Combined targeted therapy and immunotherapy for cancer treatment. World Journal of Clinical Cases, 9(26), 7643.
85. Papazoglou, D. (2022). Modelling the ability of targeted drugs and immunotherapy to modulate anti-tumour T cell activity in Chronic Lymphocytic Leukaemia (Doctoral dissertation, King's College London).
86. Kater, A. P., Wu, J. Q., Kipps, T., Eichhorst, B., Hillmen, P., D'Rozario, J., Assouline, S., Owen, C., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Dubois, J., Eldering,

E., Mellink, C., Van Der Kevie-Kersemaekers, A. M., Kim, S. Y., Chyla, B., Punnoose, E., … Seymour, J. F. (2020). Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 38(34), 4042–4054. https://doi.org/10.1200/JCO.20.00948

87. Kantarjian, H. M., DiNardo, C. D., Kadia, T. M., Daver, N. G., Altman, J. K., Stein, E. M., ... & Ravandi, F. (2025). Acute myeloid leukemia management and research in 2025. CA: a cancer journal for clinicians, 75(1), 46-67.
88. Shokoohi, M., Ghaderi, M., Mokarami, M., Arian, H., Mohammadnabi, S., & Farokhi, A. (2025). Targeted and epigenetic therapies for acute myeloid leukemia treatment. Discover Oncology, 16(1), 1711.
89. Xu, J., Dong, X., Huang, D. C., Xu, P., Zhao, Q., & Chen, B. (2023). Current advances and future strategies for BCL-2 inhibitors: potent weapons against cancers. Cancers, 15(20), 4957.
90. Tang, J., Ye, X., Xu, Z., Min, T., Tian, Z., He, Y., & Jiang, B. (2025). Epigenetic mechanisms of drug resistance in acute myeloid leukemia: advances in small-molecule targeted therapy. Frontiers in Pharmacology, 16, 1672524.
91. Cao, L., Wang, Z., Cui, Y., Li, Y., & Xiang, Q. (2025). Emerging strategies and novel therapeutic targets in acute myeloid leukemia: current advances and future directions. Biomarker Research, 13(1), 127.
92. Zheng, D., Preuss, K., Milano, M. T., He, X., Gou, L., Shi, Y., ... & Zhang, C. (2025). Mathematical modeling in radiotherapy for cancer: A comprehensive narrative review. Radiation Oncology, 20(1), 49.
93. Zhong, Z., Yao, R., Duan, Y., Ouyang, C., Du, Z., Li, L., ... & Chen, C. (2025). Advances and Challenges in Targeted Therapy and Its Combination Strategies for Leukemia. Biomedicines, 13(7), 1652.
94. Chaux, A. (2025). Molecular Mechanisms of Targeted Therapy Resistance in Genitourinary Tumors: A Path to New Therapeutic Horizons.
95. Bishoyi, A. K., Nouri, S., Hussen, A., Bayani, A., Khaksari, M. N., & Soleimani Samarkhazan, H. (2025). Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation. Clinical and Experimental Medicine, 25(1), 166.
96. Resistance can be primary (i.e., no response at onset) or acquired (i.e., an initial response followed by relapse)
97. Wang, H., Niu, X., Jin, Z., Zhang, S., Fan, R., Xiao, H., & Hu, S. S. (2025). Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities. Journal of Experimental & Clinical Cancer Research, 44(1), 250.
98. Jayavel, S., Subramanian, M., Kesavan, P. K., & Jayavel, S. (2025). Current and future of targeted therapies against BCR: ABL kinases. Journal of the Egyptian National Cancer Institute, 37(1), 12.
99. Jayavel, S., Subramanian, M., Kesavan, P. K., & Jayavel, S. (2025). Current and future of targeted therapies against BCR: ABL kinases. Journal of the Egyptian National Cancer Institute, 37(1), 12.
100. Koffi, K. G., Bognini, S. A., Silué, D. A., Kamara, I., Kouakou, I., Ruth, D., ... & Okou, D. T. (2025). BCR: ABL1 Kinase Domain Mutations and Their Predictive Value for Treatment Outcomes in Patients with Chronic Myeloid Leukemia Treated with First-Line Imatinib in a Low-Income Setting: Experience from Côte d'Ivoire. Leukemia Research Reports, 100544.
101. Wang, Y., Jiang, C., Zhou, H., & Han, R. (2025). Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer. Experimental hematology & oncology, 14(1), 114.
102. To, V., Evtimov, V. J., Jenkin, G., Pupovac, A., Trounson, A. O., & Boyd, R. L. (2022). CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies. Frontiers in Immunology, 13, 968395.
103. Cao, H., Wu, T., Zhou, X., Xie, S., Sun, H., Sun, Y., & Li, Y. (2023). Progress of research on

PD-1/PD-L1 in leukemia. Frontiers in Immunology, 14, 1265299.
104. Zhang, Y., & Wang, W. (2025). Advances in tumor subclone formation and mechanisms of growth and invasion. Journal of Translational Medicine, 23(1), 461.
105. Galitzia, A., Maccaferri, M., Mauro, F. R., Murru, R., & Marasca, R. (2024). Chronic lymphocytic leukemia: management of adverse events in the era of targeted agents. Cancers, 16(11), 1996.
106. Anderson, M. A., Walewska, R., Hackett, F., Kater, A. P., Montegaard, J., O'Brien, S., ... & Brown, J. R. (2024). Venetoclax initiation in chronic lymphocytic leukemia: international insights and innovative approaches for optimal patient care. Cancers, 16(5), 980.
107. Wu, X. A., Quan, D., Li, W., Wisskirchen, K., Wu, W., Zhou, Y., ... & Qu, X. (2025). Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial. Gut.
108. Hammad, A., & Abu-Zaid, R. (2024). Applications of AI in decentralized computing systems: harnessing artificial intelligence for enhanced scalability, efficiency, and autonomous decision-making in distributed architectures. Applied Research in Artificial Intelligence and Cloud Computing, 7(6), 161-187.
109. Bewersdorf, J. P., & Abdel-Wahab, O. (2022). Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic. Genes & Development, 36(5-6), 259-277.
110. Alaoui Mdarhri, H., Benmessaoud, R., Yacoubi, H., Seffar, L., Guennouni Assimi, H., Hamam, M., ... & Kettani-Halabi, M. (2022). Alternatives therapeutic approaches to conventional antibiotics: advantages, limitations and potential application in medicine. Antibiotics, 11(12), 1826.
111. Garciaz, S., & Hospital, M. A. (2023). FMS-like tyrosine kinase 3 inhibitors in the treatment of acute myeloid leukemia: an update on the emerging evidence and safety profile. OncoTargets and Therapy, 31-45.
112. Wang, Y., Chen, Y., Ji, D., Ge, L., Zhang, Y., Liu, L., ... & Xia, L. (2025). Meta-analysis on the effectiveness and safety of venetoclax-based combination therapy with hypomethylation in acute myeloid leukemia. European Journal of Medical Research, 30(1), 1-12.
113. Mato, A. R., Woyach, J. A., Brown, J. R., Ghia, P., Patel, K., Eyre, T. A., ... & Jurczak, W. (2023). Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. New England Journal of Medicine, 389(1), 33-44.
114. Dykes, K. C., & Ball, E. D. (2025). A review of antibody-based immunotherapy clinical trials for adult acute myeloid leukemia (AML): monoclonal antibodies (mAbs) and beyond. Expert Opinion on Biological Therapy, 25(4), 345-362.
115. Kalim, M., Jing, R., Li, X., Jiang, Z., Zheng, N., Wang, Z., ... & Lu, Y. (2024). Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy. Journal of cellular immunology, 6(1), 22.
116. Giorgioni, L., Ambrosone, A., Cometa, M. F., Salvati, A. L., Nisticò, R., & Magrelli, A. (2024). Revolutionizing CAR T-cell therapies: innovations in genetic engineering and manufacturing to enhance efficacy and accessibility. International Journal of Molecular Sciences, 25(19), 10365.
117. Turkalj, S., Radtke, F. A., & Vyas, P. (2023). An overview of targeted therapies in acute myeloid leukemia. Hemasphere, 7(6), e914.
118. Molla, G., & Bitew, M. (2025). The future of cancer diagnosis and treatment: Unlocking the power of biomarkers and personalized molecular-targeted therapies. Journal of Molecular Pathology, 6(3), 20.
119. Erba, H. P., Montesinos, P., Kim, H. J., Patkowska, E., Vrhovac, R., Žák, P., Wang, P. N., Mitov, T., Hanyok, J., Kamel, Y. M., Rohrbach, J. E. C., Liu, L., Benzohra, A., Lesegretain, A., Cortes, J., Perl, A. E., Sekeres, M. A., Dombret, H., Amadori, S., Wang, J., … QuANTUM-First Study Group (2023). Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet

(London, England), 401(10388), 1571–1583. https://doi.org/10.1016/S0140-6736(23)00464-6

120. Liu, Y., Zhang, Y., Gao, J., Wang, L., Xie, F., Zhang, C., Mao, P., & Yan, J. (2025). Venetoclax and hypomethylating agents versus induction chemotherapy for newly diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis. BMC cancer, 25(1), 894. https://doi.org/10.1186/s12885-025-14311-9
121. Aslan, B., Kismali, G., Iles, L.R. et al. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J. 12, 80 (2022). https://doi.org/10.1038/s41408-022-00675-9
122. Meckler, J. F., Levis, D. J., Vang, D. P., & Tuscano, J. M. (2023). A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model. Cancer immunology, immunotherapy: CII, 72(9), 2939–2948. https://doi.org/10.1007/s00262-023-03444-0
123. Zugasti, I., Espinosa-Aroca, L., Fidyt, K. et al. CAR-T cell therapy for cancer: current challenges and future directions. Sig Transduct Target Ther 10, 210 (2025). https://doi.org/10.1038/s41392-025-02269-w
124. Zugasti, I., Espinosa-Aroca, L., Fidyt, K. et al. CAR-T cell therapy for cancer: current challenges and future directions. Sig Transduct Target Ther 10, 210 (2025). https://doi.org/10.1038/s41392-025-02269-w
125. Jiang, N., Yang, Z., Miao, H. et al. Recent advances in universal chimeric antigen receptor T cell therapy. J Hematol Oncol 18, 82 (2025). https://doi.org/10.1186/s13045-025-01737-8
126. Hanahan, D. (2022). Hallmarks of cancer: new dimensions. Cancer discovery, 12(1), 31-46.
127. Bi, J., & Zhou, H. (2025). Targeting menin in lysine methyltransferase 2A/nucleophosmin-mutated leukemia: A novel strategy from epigenetic dysregulation to clinical therapy. Oncology Letters, 30(5), 1-10.
128. Bi, J., & Zhou, H. (2025). Targeting menin in lysine methyltransferase 2A/nucleophosmin-mutated leukemia: A novel strategy from epigenetic dysregulation to clinical therapy. Oncology Letters, 30(5), 1-10

Cite: Kartik, Rajinderpal Kaur, Nisha*, Targeted and Immune-Based Therapies in Leukemia: Current Status and Future Prospects, Int. J. Med. Pharm. Sci., 2026, 2 (4), 100-117. https://doi.org/10.5281/zenodo.19475061